vs

Side-by-side financial comparison of Penumbra Inc (PEN) and Real Brokerage Inc (REAX). Click either name above to swap in a different company.

Real Brokerage Inc is the larger business by last-quarter revenue ($568.5M vs $385.4M, roughly 1.5× Penumbra Inc). Penumbra Inc runs the higher net margin — 12.3% vs -0.1%, a 12.4% gap on every dollar of revenue. On growth, Real Brokerage Inc posted the faster year-over-year revenue change (52.6% vs 22.1%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $8.4M).

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

Anywhere Real Estate Inc., formerly Realogy, was an American real estate services firm. It operated and franchised real estate brands that provided brokerage, relocation, title, insurance, and settlement services. Brands included Better Homes and Gardens Real Estate, Century 21 Real Estate, Coldwell Banker, Corcoran Group, ERA Real Estate and Sotheby's International Realty. In 2026, the company was acquired by Compass, Inc.

PEN vs REAX — Head-to-Head

Bigger by revenue
REAX
REAX
1.5× larger
REAX
$568.5M
$385.4M
PEN
Growing faster (revenue YoY)
REAX
REAX
+30.5% gap
REAX
52.6%
22.1%
PEN
Higher net margin
PEN
PEN
12.4% more per $
PEN
12.3%
-0.1%
REAX
More free cash flow
PEN
PEN
$59.6M more FCF
PEN
$68.0M
$8.4M
REAX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PEN
PEN
REAX
REAX
Revenue
$385.4M
$568.5M
Net Profit
$47.3M
$-447.0K
Gross Margin
68.0%
7.9%
Operating Margin
15.4%
-0.1%
Net Margin
12.3%
-0.1%
Revenue YoY
22.1%
52.6%
Net Profit YoY
40.6%
82.7%
EPS (diluted)
$1.20
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PEN
PEN
REAX
REAX
Q4 25
$385.4M
Q3 25
$354.7M
$568.5M
Q2 25
$339.5M
$540.7M
Q1 25
$324.1M
$354.0M
Q4 24
$315.5M
Q3 24
$301.0M
$372.5M
Q2 24
$299.4M
Q1 24
$278.7M
$200.7M
Net Profit
PEN
PEN
REAX
REAX
Q4 25
$47.3M
Q3 25
$45.9M
$-447.0K
Q2 25
$45.3M
$1.5M
Q1 25
$39.2M
$-5.0M
Q4 24
$33.7M
Q3 24
$29.5M
$-2.6M
Q2 24
$-60.2M
Q1 24
$11.0M
$-16.1M
Gross Margin
PEN
PEN
REAX
REAX
Q4 25
68.0%
Q3 25
67.8%
7.9%
Q2 25
66.0%
8.9%
Q1 25
66.6%
9.6%
Q4 24
66.8%
Q3 24
66.5%
8.6%
Q2 24
54.4%
Q1 24
65.0%
10.3%
Operating Margin
PEN
PEN
REAX
REAX
Q4 25
15.4%
Q3 25
13.8%
-0.1%
Q2 25
12.0%
0.3%
Q1 25
12.4%
-1.5%
Q4 24
13.6%
Q3 24
11.7%
-0.7%
Q2 24
-27.0%
Q1 24
4.3%
-7.8%
Net Margin
PEN
PEN
REAX
REAX
Q4 25
12.3%
Q3 25
12.9%
-0.1%
Q2 25
13.3%
0.3%
Q1 25
12.1%
-1.4%
Q4 24
10.7%
Q3 24
9.8%
-0.7%
Q2 24
-20.1%
Q1 24
3.9%
-8.0%
EPS (diluted)
PEN
PEN
REAX
REAX
Q4 25
$1.20
Q3 25
$1.17
$0.00
Q2 25
$1.15
$0.01
Q1 25
$1.00
$-0.02
Q4 24
$0.88
Q3 24
$0.75
$-0.01
Q2 24
$-1.55
Q1 24
$0.28
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PEN
PEN
REAX
REAX
Cash + ST InvestmentsLiquidity on hand
$186.9M
$38.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
$53.6M
Total Assets
$1.8B
$145.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PEN
PEN
REAX
REAX
Q4 25
$186.9M
Q3 25
$321.0M
$38.7M
Q2 25
$421.8M
$49.7M
Q1 25
$376.1M
$24.7M
Q4 24
$324.4M
Q3 24
$280.5M
$22.6M
Q2 24
$288.3M
Q1 24
$223.1M
$20.1M
Stockholders' Equity
PEN
PEN
REAX
REAX
Q4 25
$1.4B
Q3 25
$1.4B
$53.6M
Q2 25
$1.3B
$49.2M
Q1 25
$1.2B
$32.8M
Q4 24
$1.2B
Q3 24
$1.1B
$29.8M
Q2 24
$1.2B
Q1 24
$1.2B
$25.6M
Total Assets
PEN
PEN
REAX
REAX
Q4 25
$1.8B
Q3 25
$1.7B
$145.2M
Q2 25
$1.7B
$149.4M
Q1 25
$1.6B
$100.5M
Q4 24
$1.5B
Q3 24
$1.5B
$102.5M
Q2 24
$1.5B
Q1 24
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PEN
PEN
REAX
REAX
Operating Cash FlowLast quarter
$86.5M
$8.8M
Free Cash FlowOCF − Capex
$68.0M
$8.4M
FCF MarginFCF / Revenue
17.7%
1.5%
Capex IntensityCapex / Revenue
4.8%
0.1%
Cash ConversionOCF / Net Profit
1.83×
TTM Free Cash FlowTrailing 4 quarters
$174.9M
$71.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PEN
PEN
REAX
REAX
Q4 25
$86.5M
Q3 25
$58.3M
$8.8M
Q2 25
$44.9M
$41.0M
Q1 25
$49.0M
$15.9M
Q4 24
$51.1M
Q3 24
$56.5M
$7.2M
Q2 24
$22.6M
Q1 24
$38.3M
$21.5M
Free Cash Flow
PEN
PEN
REAX
REAX
Q4 25
$68.0M
Q3 25
$42.0M
$8.4M
Q2 25
$29.4M
$40.8M
Q1 25
$35.5M
$15.7M
Q4 24
$45.7M
Q3 24
$51.0M
$6.8M
Q2 24
$18.1M
Q1 24
$32.5M
$21.4M
FCF Margin
PEN
PEN
REAX
REAX
Q4 25
17.7%
Q3 25
11.8%
1.5%
Q2 25
8.7%
7.5%
Q1 25
11.0%
4.4%
Q4 24
14.5%
Q3 24
16.9%
1.8%
Q2 24
6.0%
Q1 24
11.7%
10.7%
Capex Intensity
PEN
PEN
REAX
REAX
Q4 25
4.8%
Q3 25
4.6%
0.1%
Q2 25
4.6%
0.0%
Q1 25
4.2%
0.1%
Q4 24
1.7%
Q3 24
1.8%
0.1%
Q2 24
1.5%
Q1 24
2.1%
0.0%
Cash Conversion
PEN
PEN
REAX
REAX
Q4 25
1.83×
Q3 25
1.27×
Q2 25
0.99×
27.13×
Q1 25
1.25×
Q4 24
1.52×
Q3 24
1.91×
Q2 24
Q1 24
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PEN
PEN

Thrombectomy$254.7M66%
Other$130.7M34%

REAX
REAX

Segment breakdown not available.

Related Comparisons